Skyrizi 600 mg/10mL (Risankizumab-Rzaa INJECTION) 600 mg/10mL

Skyrizi 600 mg/10mL injection is a medication used for managing specific inflammatory conditions. This single-dose vial is designed for intravenous administration and is manufactured by AbbVie Inc. in the USA.

Strength

600 mg/10mL

Pack Size

1 VIAL, SINGLE-DOSE in 1 CARTON (0074-5015-02) / 10 mL in 1 VIAL, SINGLE-DOSE

Manufacturer / TM Owner

AbbVie Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Skyrizi 600 mg/10mL injection is primarily used for the treatment of moderate to severe plaque psoriasis, a skin condition characterized by red, itchy, and scaly patches. It may also be prescribed for other inflammatory conditions as determined by a healthcare provider. The active ingredient, risankizumab-rzaa, works by targeting specific proteins involved in the inflammatory process.

Side Effects

Common effects of Skyrizi 600 mg/10mL injection may include reactions at the injection site, such as redness, itching, or swelling. Some individuals might experience fatigue, headache, or upper respiratory infections. These effects vary and are not experienced by everyone.

Precautions & Warnings

Skyrizi 600 mg/10mL injection should be handled with care, ensuring proper storage and administration as directed. It is important to inform healthcare providers about any allergies or existing medical conditions before use. This medication should only be administered by a healthcare professional.

Avoid Interactions

Skyrizi 600 mg/10mL injection may interact with other medications, including those that affect the immune system. It is advisable to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also influence the effectiveness of this treatment.

Frequently Asked Questions

Skyrizi 600 mg/10mL injection is primarily used for managing moderate to severe plaque psoriasis and other inflammatory conditions.

Skyrizi 600 mg/10mL injection is administered intravenously by a healthcare professional.

Common effects may include injection site reactions, fatigue, headache, and upper respiratory infections.

Potential interactions with other medications should be discussed with a healthcare provider to ensure safety.

Skyrizi 600 mg/10mL injection is manufactured by AbbVie Inc. in the USA.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.